NPF-Funded Research

Degrading CARD14 to Treat Psoriasis

Headshot to be 275 x 275 px

Principal Investigator: Anne Bowcock, Ph.D.
Institution:
Icahn School of Medicine at Mount Sinai


Grant Mechanism: Translational Research Grant
Funding Amount: $200,000
Project Start Date: August 1, 2024
Project End Date: July 31, 2026
Status: Active
Keywords: Psoriasis, Animal Models, Drug Therapy, Cell Signaling

Project Summary:

Although biologics have been spectacularly successful they need to be injected and may have long-term effects. We propose a novel approach to psoriasis. We will focus on a protein we identified a few years ago (CARD14) that is central to early alterations arising in psoriatic skin. We will target activated CARD14 for degradation via a novel technology (Bridged-PROTAC). We have identified 29 degraders and will identify additional compounds. We will evaluate their sensitivity and specificity in cell-based systems and animals. We will ultimately evaluate these compounds in animal models of psoriasis, with the long-term goal of taking this to the clinic. This approach could also be applicable to other alterations that arise in psoriasis.

How will your project help improve the lives of the 125 million affected by psoriatic disease?

Why is psoriatic disease research important to you, personally? What role will this award play in your research efforts or career development?






Researcher Profile:

Impact of NPF-Funded Research

The NPF has awarded over $30 million in research funding in recent years, with immeasurable impact on our community.

Read more

We Need Your Help

With your gift we can fund even more research to get better treatment and diagnostic options and someday, a cure.

Help fund critical research

NPF-Funded Research

Discover our other active research projects.

Learn more

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2024 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.